Trial Profile
A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs ALD 301 (Primary)
- Indications Peripheral arterial occlusive disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aldagen
- 12 May 2014 New trial record